MORE Opioid Misuse is drawing attention because recent research links Mindfulness-Oriented Recovery Enhancement with both clinical outcomes and projected economic savings. The claim deserves a careful reading: economic value is not the same as individual suitability, and no stress-management practice should be treated as a stand-alone answer for opioid misuse, chronic pain, withdrawal risk, or medication decisions.
As a stress management consultant, I read these findings through the lens of regulation, attention, and support systems. Breath awareness and mindfulness can be part of stress education, but the figures discussed here are specifically about MORE, not generic breathing exercises. People facing opioid misuse, chronic pain, or medication questions should seek medical advice from a qualified professional.
What MORE Opioid Misuse Economics Show
Projected Savings And Social Costs
A University of Utah Health report dated August 5, 2026 stated that for each dollar invested in MORE, society gains about 12 dollars in savings, with estimated lifetime cost savings of about 324,489 dollars per patient. The same report stated that this cost-benefit ratio was two to six times higher than many other addiction treatments, and that major savings came from projected reductions in healthcare utilization, criminal justice involvement, lost productivity, and overdose mortality University of Utah Health report.
Those numbers are striking, but they should be interpreted as economic modeling rather than a guarantee for any one person. A model can estimate social costs avoided across a population, yet individual outcomes vary by health status, pain history, mental health needs, medication use, access to trained clinicians, and the intensity of surrounding care. Cost savings may help policymakers and health systems ask better questions, but they do not replace clinical judgment.
MORE Opioid Misuse And Trial Context
The economic case is connected to clinical research, including a randomized clinical trial involving 250 adults with chronic pain who were misusing opioids. Participants were recruited from January 4, 2016, through January 16, 2020. At the nine-month follow-up, 45.0 percent of participants in the MORE intervention were no longer misusing opioids, compared with 24.4 percent in a supportive group psychotherapy control condition. The trial also reported greater improvements in pain severity and pain-related functional interference for the MORE group randomized clinical trial.
For MORE Opioid Misuse, this matters because economic value usually depends on more than the cost of delivering sessions. If a program is associated with reductions in opioid misuse, pain interference, or related service use in a studied population, those changes can affect downstream costs. Still, the trial population, comparison condition, follow-up period, and delivery setting all shape how far the findings can reasonably be applied.
Why Cost Savings Need Cautious Interpretation
Economic Value Is Not The Same As Access
Large projected savings can make an intervention look efficient on paper, but access can be uneven in real practice. A therapy may require trained providers, scheduling capacity, referral pathways, payer coverage, and patient willingness to participate. If those pieces are missing, the modeled savings may not appear in the same way. Economic studies are useful for planning, yet implementation often decides whether an evidence-informed approach reaches the people it was designed to serve.
There is also a timing issue. Some costs of care occur early, while some benefits may accrue later through reduced healthcare utilization, improved functioning, or lower social costs. A clinic, insurer, public agency, and patient may not all experience costs and savings at the same point. That difference can affect whether a program is funded, even when the broader social estimate appears favorable.
The Role Of Stress Regulation
Mindfulness-oriented programs are often discussed alongside stress regulation because attention, craving, pain, and emotional distress can influence one another. From a breathwork perspective, it is tempting to focus on the calming aspect alone. That would be too narrow. The research summarized above concerns a structured intervention tested in clinical contexts, not a casual relaxation tip. Calm may be helpful for some people in some moments, but opioid misuse requires qualified assessment and coordinated care.
Readers interested in exploring related wellness education within the network might visit Petra Class, which offers similar resources.
How Policymakers And Care Teams Might Read The Evidence
Questions For Health Systems
For health systems, the key question is not simply whether MORE appears promising. A stronger question is whether the local setting can deliver the intervention with fidelity, appropriate supervision, and integration with existing care. The reported savings categories—healthcare utilization, criminal justice involvement, lost productivity, and overdose mortality—suggest that the economic effects may extend beyond a single clinic budget.
That wider view can be useful for public health planning. If one agency pays for an intervention but another sector receives much of the savings, coordination may be needed. Economic findings can support conversations between healthcare organizations, public agencies, and payers, but they should not be used as proof that the same return will occur in every community.
Questions For Patients And Families
For patients and families, the more immediate concern is safety and fit. Opioid misuse and chronic pain can involve medical, psychological, and social risks that should not be handled alone. Medical advice should be sought from a qualified professional, especially before changing medications, altering pain treatment, or choosing among therapy options. A clinician can explain whether a mindfulness-oriented program is appropriate alongside other forms of care.
It may also help to ask how outcomes are monitored. In research, measures such as opioid misuse status, pain severity, and pain-related functional interference can be tracked over time. In clinical practice, a care team may use different tools, but the principle is similar: decisions should be guided by observable change, safety, and patient needs rather than by enthusiasm for any single approach.
Questions To Ask About MORE Opioid Misuse
The practical question around MORE Opioid Misuse is not whether mindfulness is good or bad. The better question is where a structured intervention may fit within evidence-informed care, and what level of evidence supports that use. The August 5, 2026 economic report suggests a large return on investment, while the randomized clinical trial provides clinical context in adults with chronic pain who were misusing opioids.
- What training and supervision do providers have in delivering MORE?
- How would this program fit with current pain care, mental health care, or medication treatment?
- What outcomes would be monitored, and over what follow-up period?
- What risks, access barriers, or alternatives should be discussed before starting?
These are not abstract questions. They help separate a promising economic analysis from personal medical decision-making. Anyone affected by opioid misuse, chronic pain, medication concerns, or withdrawal risk should discuss options with a qualified clinician or appropriate care team. Evidence can inform the conversation, but individual medical advice should come from a licensed professional who understands the person’s full situation.